Pembrolizumab (Keytruda®) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Pembrolizumab ELISA kit is designed to detect antibody against Pembrolizumab with high specificity and sensitivity in biological matrices.
产品特点
Easy, convenient, sensitive and time-saving method toqualitative determination of antibody against Pembrolizumab (Keytruda) in human serum and plasma.
Cross Reactivity: Pembrolizumab (Keytruda
